Cauda equine syndrome as the primary symptom of leptomeningeal metastases from lung cancer: a case report and review of literature

Yang Liu*
Bin Wang*
Yongxiang Qian
Dongmei Di
Min Wang
Xiaoying Zhang

Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China

*These authors contributed equally to this work

Abstract: Cauda equine syndrome (CES) is a neurological condition caused by compression of the cauda equine. Here, we demonstrate a case of CES as the primary symptom of leptomeningeal metastases from non-small cell lung carcinoma without brain metastases. A 59-year-old male suffered progressive lower extremity motor dysfunction, urinary dysfunction, and lower extremity sensory dysfunction. He was clinically diagnosed with CES. Nuclear magnetic resonance imaging demonstrated several vague nodules in the area of conus medullaris and cauda equine, without lumbar or thoracic herniated discs. The serum carcinoembryonic antigen concentration was 191.20 ng/mL. The conclusion following positron emission tomography–computed tomography was a right upper lung malignant tumor with mediastinal lymph node metastasis and cauda equina metastasis. Pathologic diagnosis was of primary adenocarcinoma of the lung by bronchoscopic biopsy. EML4–ALK fusion and EGFR mutations were absent, and thus the patient received chemotherapy. However, symptoms of intracranial hypertension arose 1 month later, and the patient died 3 months postadmission. Emerging CES may be a sign of metastasis of a malignant tumor, presenting an extremely challenging condition, especially for patients with lung cancer. Positron emission tomography–computed tomography is a fairly effective technique to make the diagnosis.

Keywords: cauda equine syndrome, leptomeningeal carcinomatosis, positron emission tomography–computed tomography, lung cancer

Introduction
Cauda equine syndrome (CES) is a neurological condition caused by compression of the cauda equine, and patients present with lower back pain, bilateral sciatica, saddle sensory disturbances, bladder and bowel dysfunction, and loss of sensory and motor function in the lower extremities.1 Common pathologies of CES include lumbar herniated disc, tumor, and infection.2 Leptomeningeal carcinomatosis arises from multifocal seeding of the leptomeninges by malignant cells, and presents in 1%–8% of patients with solid tumors, the majority of which are lung and breast cancers.3 Leptomeningeal carcinomatosis is a serious complication, with a median survival of 1.3 months without appropriate therapy.4 It is also unusual to present with leptomeningeal carcinomatosis without brain metastases.

Here, we demonstrate a case of CES as the primary symptom of leptomeningeal metastases from non-small cell lung cancer (NSCLC) without brain metastases.

Case report
A 59-year-old male suffered progressive sensory dysfunction in his lower extremities, arising 1 month prior to assessment, which was followed by urinary dysfunction and lower extremity motor dysfunction. He was clinically diagnosed with CES. Nuclear
magnetic resonance image demonstrated several vague nodules in the area of conus medullaris and cauda equina, without evidence of herniation of the lumbar or thoracic discs (Figure 1A). The physicians came across a mass in the right upper lobe by thoracic computer tomography. The serum carcinoembryonic antigen concentration was 191.20 ng/mL, which is 40 times the normal level.

The patient was then transferred to our hospital. Considering several tumor markers were abnormally elevated, we carried out positron emission tomography–computed tomography (PET/CT) immediately. PET images demonstrated an annular lesion with abnormal [18F]-fluorodeoxyglucose (FDG) accumulation in the right upper lobe, with a diameter of 3.2 cm and a maximum standardized uptake value (SUV$_{\text{max}}$) of 16.9 (kBq/mL)/MBq/kg. Moreover, there were several nodules with enhanced FDG accumulation in the right lateral trachea, anterior to the carina and hilum, with the largest reaching 2.1 cm in size with an SUV$_{\text{max}}$ of 21.0 (kBq/mL)/MBq/kg (Figure 1B and C). CT images showed the presence of a mass with lobulated/spiculated borders in the right upper lobe. Furthermore, we found several nodules with increased FDG accumulation in the lumbosacral spinal cord, without lumbar vertebral destruction, whose SUV$_{\text{max}}$ was 9.4 (kBq/mL)/MBq/kg. We came to the diagnosis of a right upper lung malignant tumor with mediastinal lymph nodes metastasis and cauda equina metastasis.

The patient underwent a bronchoscopic biopsy of the peripheral lung lesions, and was diagnosed with primary adenocarcinoma of the lung. An amplification refractory mutation system was applied to test for the presence of EML4–ALK fusion and/or mutations in EGFR, which includes deletions within exon 19, the G719X mutation in exon 18, the S768I mutation in exon 20, and the L858R mutation in exon 21. None of these common mutations were detected.

As chemotherapy was advised, cisplatin and pemetrexed disodium were administered to the patient. However, his physiological status deteriorated 1 week following chemotherapy treatment, and the patient and family members refused sequential courses of chemotherapy. Symptoms of intracranial hypertension arose 1 month later, and the patient died 3 months following admission.

Discussion
Spinal cord or cauda equina compression is increasing in patients with malignant tumors because of prolonged survival. Metastatic tumors can be seen in extradural, intradural extramedullary, and intramedullary locations, with no survival difference observed among these localizations. Intradural parenchymal involvement, a rare complication, can arise in 1.65% of patients with primary lung cancer, which is mostly derived from hematogenous dissemination, including from arterial and vertebral venous plexus routes. Meningeal carcinomatosis can also be combined with intradural parenchymal involvement. Cauda equina compression by metastatic lung cancer affects men more than women.

Although rare, these patients have a poor prognosis. It was reported that 10 out of 131 patients presenting neurological symptoms resulting from spinal metastases displayed compression of the conus medullaris or cauda equina. Most of these neurological symptoms originated from lung cancer (33%). Only 17% of patients with lung cancer responded well to treatment, and only 2% survived over 1 year. Before the 1990s, patients with intradural parenchymal involvement because of primary lung cancer only survived an average of 110 days. Patients with leptomeningeal metastases had a prognosis of 6 months survival with normal cerebrospinal fluid flow, and 4 months survival when displaying interrupted cerebrospinal
fluid flow.\textsuperscript{9} Gwak et al\textsuperscript{10} reported that patients with leptomeningeal carcinomatosis from NSCLC could only survive for 3 months while undergoing intraventricular chemotherapy.

Gwak et al\textsuperscript{10} also pointed out that younger age, better Karnofsky performance score, controlled intracranial pressure, greater amount of intraventricular chemotherapy, concurrent systemic chemotherapy, and receptor tyrosine kinase inhibitor administration were favorable prognostic factors. Among all variables, a better Karnofsky performance score is the strongest prognostic factor (hazard ratio: 2.57).\textsuperscript{10} Irradiation and corticosteroids have also been shown to be useful for relieving leg and back pain.\textsuperscript{11} Gefitinib, a tyrosine kinase inhibitor, has been shown to be effective in the treatment of neurological symptoms.\textsuperscript{12} Surgical removal of the intradural extramedullary mass can relieve CES, especially when presenting with impaired sphincter function, even if it has not been shown to help to improve survival times.\textsuperscript{13}

In a review of the relevant literature, we examined 13 studies of CES related to lung cancer. We list the details of these articles in Table 1.

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Pathology</th>
<th>Survival time</th>
<th>Treatment</th>
<th>Symptoms improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leviov et al\textsuperscript{11}</td>
<td>7</td>
<td>UN</td>
<td>10 months in ambulant patients, 2 months in non-ambulant patients</td>
<td>High dose of dexamethasone and spinal irradiation</td>
<td>2 of 7 patients recovered</td>
</tr>
<tr>
<td>Chamberlain and Kormanik\textsuperscript{1}</td>
<td>3</td>
<td>UN</td>
<td>1, 3, 8 months</td>
<td>Intrathecal chemotherapy</td>
<td>Partially responded</td>
</tr>
<tr>
<td>Okamoto et al\textsuperscript{7}</td>
<td>9</td>
<td>3 AC, 6 SCLC</td>
<td>Mean: 116 days, 28–220 days</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ampil et al\textsuperscript{14}</td>
<td>16</td>
<td>UN</td>
<td>Mean: 3 months</td>
<td>Corticosteroid therapy and conventional megavoltage radiotherapy</td>
<td>Clinical manifestations improved</td>
</tr>
<tr>
<td>Sakai et al\textsuperscript{9}</td>
<td>1</td>
<td>AC</td>
<td>&gt;8 months</td>
<td>Gefitinib</td>
<td>Recovered and was able to work</td>
</tr>
<tr>
<td>Kotil et al\textsuperscript{15}</td>
<td>1</td>
<td>AC</td>
<td>&gt;12 months</td>
<td>Laminectomy, radiotherapy, and chemotherapy</td>
<td>Recovered 12 months postoperation</td>
</tr>
<tr>
<td>Walid et al\textsuperscript{3}</td>
<td>1</td>
<td>SCLC</td>
<td>&gt;10 months</td>
<td>Intrathecal chemotherapy, spinal radiotherapy, and systemic chemotherapy</td>
<td>Improved after systemic chemotherapy</td>
</tr>
<tr>
<td>Löhr et al\textsuperscript{16}</td>
<td>2</td>
<td>1 SC, 1 AC</td>
<td>1.5 and 8 months</td>
<td>Interlaminar fenestration and subtotal resection, hemilaminectomy and total resection of tumor</td>
<td>Pain relieved and neurological function improved</td>
</tr>
<tr>
<td>Alicioglu and Saynak\textsuperscript{17}</td>
<td>1</td>
<td>SC</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Lin et al\textsuperscript{18}</td>
<td>1</td>
<td>SCLC</td>
<td>3 months</td>
<td>Laminectomy and local spinal radiotherapy (20)</td>
<td>Back pain improved</td>
</tr>
<tr>
<td>Tsimpas et al\textsuperscript{19}</td>
<td>1</td>
<td>LCNC</td>
<td>&gt;12 months</td>
<td>Laminectomy, systemic chemotherapy</td>
<td>Pain and urination function improved</td>
</tr>
<tr>
<td>Xiong and Zhang\textsuperscript{11}</td>
<td>1</td>
<td>SCLC</td>
<td>12 months</td>
<td>Intraventricular chemotherapy, with or without systemic chemotherapy</td>
<td>2 of 13 patients recovered</td>
</tr>
<tr>
<td>Gwak et al\textsuperscript{10}</td>
<td>13</td>
<td>NSCLC</td>
<td>Mean: 3 months, 0.5–21.5 months</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Note: ‘\textsuperscript{-}’ = No data.

Abbreviations: CES, cauda equine syndrome; UN, unknown; AC, adenocarcinoma; SC, squamous carcinoma; SCLC, small-cell lung cancer; NSCLC, non-small-cell lung cancer; LCNC, large-cell neuroendocrine carcinoma.
interventions survived an average of 10.8 months.\textsuperscript{3,12,13,15,19} Chemotherapy is the basic therapy for these patients. However, tyrosine kinase inhibitor treatment is the most effective therapy, which should be the first choice for patients with EGFR mutations. Laminectomy and tumor excision can significantly relieve cauda equine compression, which when combined with radiotherapy or chemotherapy can prolong life expectancy but has no increased survival effect on its own. Radiotherapy is considered a low palliative intervention, which can be an adjuvant treatment especially for squamous cell carcinomas. Intrasacral chemotherapy can be used to treat subclinical leptomeningeal deposits and tumor cells in the cerebrospinal fluid.\textsuperscript{20}

**Conclusion**
Emerging CES may be a sign of metastasis of a malignant tumor, presenting an extremely challenging condition, especially for patients with lung cancer. Oncologists should have familiarity with this disease, and the use of PET/CT is a fairly effective technique to make the diagnosis. Tyrosine kinase inhibitor treatment is the most effective therapy, and combined medical therapies can also prolong a patient’s life, including chemotherapy, radiotherapy, and laminectomy.

**Consent for publication**
The patient provided written informed consent for this study. Written informed consent for publication of the clinical details and/or clinical images was obtained from the patient’s family.

**Ethics approval**
The Ethics Committee of the Third Affiliated Hospital of Soochow University approved this study. The analysis was performed in accordance with the ethical standards of the hospital.

**Acknowledgments**
This study was supported by The National Natural Science Fund (81701584) and the Natural Science Foundation of Changzhou Municipal Government (CJ20140030).

**Author contributions**
YL collected the details of the reported patient and reviewed related articles. BW performed literature review and composed the manuscript. YQ was in-charge of the patient. DD prepared and generated the figure. MW revised the manuscript. XZ participated in sequence alignment and revised the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**